DOSAGE REGIMEN FOR A COMBINATION THERAPY CONSISTING OFTCR-ENGINEERED T-CELLS IN COMBINATION WITH A PD-1 AXIS BINDING ANTAGONIST

The disclosure relates to a method of treating cancer, and to a population of modified T cells for use in a method of treating cancer. La divulgation concerne une méthode de traitement du cancer et une population de lymphocytes T modifiés destinés à être utilisés dans une méthode de traitement du ca...

Full description

Saved in:
Bibliographic Details
Main Authors SARO, Jose, GARCIA, Alejandro, DAWE, Steve
Format Patent
LanguageEnglish
French
Published 21.12.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The disclosure relates to a method of treating cancer, and to a population of modified T cells for use in a method of treating cancer. La divulgation concerne une méthode de traitement du cancer et une population de lymphocytes T modifiés destinés à être utilisés dans une méthode de traitement du cancer.
Bibliography:Application Number: WO2023GB51565